Patient-reported outcomes in high-risk HR+/HER2-early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study
Background: The PENELOPEB trial investigating efficacy and safety of additional 1-year post-neoadjuvant pal-bociclib to standard endocrine therapy (ET) high-risk hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) early breast cancer patients failed to improve i...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
January 2024
|
| In: |
European journal of cancer
Year: 2024, Jahrgang: 196, Pages: 1-7 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2023.113420 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejca.2023.113420 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804923007220?via%3Dihub 
|
| Verfasserangaben: | Jose Angel Garcia-Saenz, Frederik Marme, Michael Untch, Herve Bonnefoi, Sung-Bae Kim, Harry Bear, Nicole Mc Carthy, Karen Gelmon, Miguel Martin, Catherine M. Kelly, Toralf Reimer, Masakazu Toi, Ernest Law, Helen Bhattacharyya, Michael Gnant, Andreas Makris, Sabine Seiler, Nicole Burchardi, Valentina Nekljudova, Sibylle Loibl, Hope S. Rugo |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1896984975 | ||
| 003 | DE-627 | ||
| 005 | 20241205155338.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240730s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2023.113420 |2 doi | |
| 035 | |a (DE-627)1896984975 | ||
| 035 | |a (DE-599)KXP1896984975 | ||
| 035 | |a (OCoLC)1475305237 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a García-Sáenz, José Angel |e VerfasserIn |0 (DE-588)133738738X |0 (DE-627)1896983871 |4 aut | |
| 245 | 1 | 0 | |a Patient-reported outcomes in high-risk HR+/HER2-early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study |c Jose Angel Garcia-Saenz, Frederik Marme, Michael Untch, Herve Bonnefoi, Sung-Bae Kim, Harry Bear, Nicole Mc Carthy, Karen Gelmon, Miguel Martin, Catherine M. Kelly, Toralf Reimer, Masakazu Toi, Ernest Law, Helen Bhattacharyya, Michael Gnant, Andreas Makris, Sabine Seiler, Nicole Burchardi, Valentina Nekljudova, Sibylle Loibl, Hope S. Rugo |
| 246 | 3 | 3 | |a Patient-reported outcomes in high-risk HR+/HER2-early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPE B study |
| 264 | 1 | |c January 2024 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Im Text ist "B" hochgestellt | ||
| 500 | |a Gesehen am 30.07.2024 | ||
| 500 | |a Online veröffentlicht: 5. November 2023, Artikelversion: 23. November 2023 | ||
| 520 | |a Background: The PENELOPEB trial investigating efficacy and safety of additional 1-year post-neoadjuvant pal-bociclib to standard endocrine therapy (ET) high-risk hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) early breast cancer patients failed to improve invasive disease-free survival (iDFS). This analysis compared patient-reported outcomes (PROs) between treatment groups.Patients and methods: Patients received 13 cycles of palbociclib 125 mg/day (n = 631) or placebo (n = 619) orally for 3 out of 4 weeks + ET. European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30), its breast cancer (BR23) and fatigue (FA13) modules, mood questionnaire GAD7 and European Quality of Life 5 Dimensions (EQ-5D) instruments were used for the assessment of quality of life (QoL). Repeated-measures mixed-effects models were used to evaluate differences in PRO, changes of PRO over time, and treatment-by-time interactions.Results: 924 of 1250 patients (73.9%) completed baseline and at least one post-baseline questionnaire of all PRO instruments. General health status (GHS)/QoL based on EORTC QLQ-C30 was high in both arms (mean [SD]: palbociclib 70.1 [19.3], placebo 71.4 [18.8]) and was slightly higher in the placebo arm (LeastSquare mean difference: 0.82, p < 0.001). Higher fatigue was reported in the palbociclib arm (mean [SD]: 30.3 [23.8] vs. placebo 28.3 [22.7]; p < 0.001). No statistically significant differences were observed among FA13 physical, cognitive, and emotional fatigue subscales.Conclusion: Patient-reported global QoL and fatigue did not substantially change in both treatment arms. Slight differences in GHS, physical functioning, and fatigue favored the placebo arm statistically without achieving clinically meaningful thresholds. | ||
| 650 | 4 | |a ADJUVANT | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a EUROPEAN-ORGANIZATION | |
| 650 | 4 | |a GUIDELINES | |
| 650 | 4 | |a High -risk HR + /HER2 early breast cancer | |
| 650 | 4 | |a Palbociclib | |
| 650 | 4 | |a PLUS FULVESTRANT | |
| 650 | 4 | |a Post-neoadjuvant | |
| 650 | 4 | |a QoL | |
| 650 | 4 | |a QUALITY-OF-LIFE | |
| 650 | 4 | |a SCORES | |
| 650 | 4 | |a TRIALS | |
| 650 | 4 | |a WOMEN | |
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 700 | 1 | |a Untch, Michael |e VerfasserIn |0 (DE-588)134268083 |0 (DE-627)566077914 |0 (DE-576)300413572 |4 aut | |
| 700 | 1 | |a Bonnefoi, Herve |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kim, Sung-Bae |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bear, Harry |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mc Carthy, Nicole |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gelmon, Karen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Martin, Miguel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kelly, Catherine M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reimer, Toralf |e VerfasserIn |4 aut | |
| 700 | 1 | |a Toi, Masakazu |e VerfasserIn |4 aut | |
| 700 | 1 | |a Law, Ernest |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bhattacharyya, Helen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gnant, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Makris, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seiler, Sabine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Burchardi, Nicole |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nekljudova, Valentina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Loibl, Sibylle |e VerfasserIn |0 (DE-588)12433024X |0 (DE-627)085790508 |0 (DE-576)294122753 |4 aut | |
| 700 | 1 | |a Rugo, Hope S. |e VerfasserIn |0 (DE-588)1020214171 |0 (DE-627)691143218 |0 (DE-576)359869203 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 196(2024), Artikel-ID 113420, Seite 1-7 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Patient-reported outcomes in high-risk HR+/HER2-early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study |
| 773 | 1 | 8 | |g volume:196 |g year:2024 |g elocationid:113420 |g pages:1-7 |g extent:7 |a Patient-reported outcomes in high-risk HR+/HER2-early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2023.113420 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0959804923007220?via%3Dihub |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240730 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 50000 |d 60000 |d 61300 |e 50000PM132561972 |e 60000PM132561972 |e 61300PM132561972 |k 0/50000/ |k 0/60000/ |k 1/60000/61300/ |p 2 | ||
| 999 | |a KXP-PPN1896984975 |e 4560424349 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"role":"aut","given":"José Angel","display":"García-Sáenz, José Angel","family":"García-Sáenz"},{"given":"Frederik","role":"aut","family":"Marmé","display":"Marmé, Frederik"},{"role":"aut","given":"Michael","family":"Untch","display":"Untch, Michael"},{"display":"Bonnefoi, Herve","family":"Bonnefoi","role":"aut","given":"Herve"},{"given":"Sung-Bae","role":"aut","display":"Kim, Sung-Bae","family":"Kim"},{"family":"Bear","display":"Bear, Harry","role":"aut","given":"Harry"},{"given":"Nicole","role":"aut","display":"Mc Carthy, Nicole","family":"Mc Carthy"},{"family":"Gelmon","display":"Gelmon, Karen","role":"aut","given":"Karen"},{"display":"Martin, Miguel","family":"Martin","given":"Miguel","role":"aut"},{"display":"Kelly, Catherine M.","family":"Kelly","role":"aut","given":"Catherine M."},{"given":"Toralf","role":"aut","family":"Reimer","display":"Reimer, Toralf"},{"role":"aut","given":"Masakazu","display":"Toi, Masakazu","family":"Toi"},{"given":"Ernest","role":"aut","display":"Law, Ernest","family":"Law"},{"given":"Helen","role":"aut","family":"Bhattacharyya","display":"Bhattacharyya, Helen"},{"role":"aut","given":"Michael","display":"Gnant, Michael","family":"Gnant"},{"display":"Makris, Andreas","family":"Makris","role":"aut","given":"Andreas"},{"family":"Seiler","display":"Seiler, Sabine","given":"Sabine","role":"aut"},{"family":"Burchardi","display":"Burchardi, Nicole","role":"aut","given":"Nicole"},{"given":"Valentina","role":"aut","display":"Nekljudova, Valentina","family":"Nekljudova"},{"role":"aut","given":"Sibylle","display":"Loibl, Sibylle","family":"Loibl"},{"role":"aut","given":"Hope S.","display":"Rugo, Hope S.","family":"Rugo"}],"note":["Im Text ist \"B\" hochgestellt","Gesehen am 30.07.2024","Online veröffentlicht: 5. November 2023, Artikelversion: 23. November 2023"],"origin":[{"dateIssuedDisp":"January 2024","dateIssuedKey":"2024"}],"title":[{"title":"Patient-reported outcomes in high-risk HR+/HER2-early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study","title_sort":"Patient-reported outcomes in high-risk HR+/HER2-early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study"}],"titleAlt":[{"title":"Patient-reported outcomes in high-risk HR+/HER2-early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPE B study"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"name":{"displayForm":["Jose Angel Garcia-Saenz, Frederik Marme, Michael Untch, Herve Bonnefoi, Sung-Bae Kim, Harry Bear, Nicole Mc Carthy, Karen Gelmon, Miguel Martin, Catherine M. Kelly, Toralf Reimer, Masakazu Toi, Ernest Law, Helen Bhattacharyya, Michael Gnant, Andreas Makris, Sabine Seiler, Nicole Burchardi, Valentina Nekljudova, Sibylle Loibl, Hope S. Rugo"]},"physDesc":[{"extent":"7 S."}],"recId":"1896984975","relHost":[{"id":{"zdb":["1468190-0"],"eki":["266883400"],"issn":["1879-0852"]},"recId":"266883400","pubHistory":["28.1992 -"],"part":{"extent":"7","volume":"196","year":"2024","pages":"1-7","text":"196(2024), Artikel-ID 113420, Seite 1-7"},"titleAlt":[{"title":"EJC online"}],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"origin":[{"dateIssuedKey":"1992","publisher":"Elsevier ; Pergamon Press","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","dateIssuedDisp":"1992-"}],"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"disp":"Patient-reported outcomes in high-risk HR+/HER2-early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB studyEuropean journal of cancer","corporate":[{"display":"European Organization for Research on Treatment of Cancer","role":"isb"},{"display":"European Association for Cancer Research","role":"isb"},{"display":"European School of Oncology","role":"isb"}]}],"id":{"eki":["1896984975"],"doi":["10.1016/j.ejca.2023.113420"]}} | ||
| SRT | |a GARCIASAENPATIENTREP2024 | ||